Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers

BACKGROUND: Guanfacine extended-release (GXR) is an orally administered, non-stimulant treatment for children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and is primarily metabolized by the 3A4 isozyme of cytochrome P450 (CYP3A4). The results of clinical pharmacokinetic (PK)...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Aiqun, Yeo, Karen, Welty, Devin, Rong, Haojing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856887/
https://www.ncbi.nlm.nih.gov/pubmed/29098603
http://dx.doi.org/10.1007/s40272-017-0270-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856887/
https://www.ncbi.nlm.nih.gov/pubmed/29098603
http://dx.doi.org/10.1007/s40272-017-0270-0

Ejemplares similares